Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Antibody-Drug-Conjugate (ADC) company reports patient death

<< Previous

Bullboard Posts

Next >>

Comment by JohnnyYegon Aug 10, 2023 6:51pm

173 Views

Post# 35582830

RE:RE:RE:RE:RE:RE:Antibody-Drug-Conjugate (ADC) company reports patient death

I don't see mBC as dead by any stretch of the imagination. They wouldn't have been given the oral presentation at ASCO and followed that with the KOL of renowned scientists if it was no longer a starter. But I do think they have to figure some things out with it before proceeding, and have PDAC and CRC moving fast into the limelight.

Too bad there isn't a "PanCAN" for breast that has us in their sites...

<< Previous

Bullboard Posts

Next >>

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal